The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy
Status:
Completed
Trial end date:
2014-12-17
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate if rifaximin alone or rifaximin plus lactulose delays
the onset of hepatic encephalopathy (HE) in participants with cirrhosis who have had a
previous episode of HE.
Phase:
Phase 4
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.